Exenatide once weekly improved 24-hour glucose control and reduced glycaemic variability in metformin-treated participants with type 2 diabetes: a randomized, placebo-controlled trial.

Frías, Juan P; Nakhle, Samer; Ruggles, James A; Zhuplatov, Sergey; Klein, Eric; Zhou, Rong; Strange, Poul

Frías, Juan P; Nakhle, Samer; Ruggles, James A; Zhuplatov, Sergey; Klein, Eric; Zhou, Rong; Strange, Poul.

Afiliação

Frías JP; National Research Institute, Los Angeles, California, USA.
Nakhle S; Palm Medical Research, Las Vegas, Nevada, USA.
Ruggles JA; Medical Affairs, AstraZeneca, Wilmington, Delaware, USA.
Zhuplatov S; Medical Affairs, AstraZeneca, Wilmington, Delaware, USA.
Klein E; Capital Clinical Research Center, Olympia, Washington, USA.
Zhou R; Department of Biostatistics, Medpace, Cincinnati, Ohio, USA.
Strange P; Integrated Medical Development, Princeton Junction, New Jersey, USA.

Diabetes Obes Metab ; 19(1): 40-48, 2017 Jan.

Article em En | MEDLINE | ID: mdl-27527911

Palavras-chave

24-hour glucose profile; continuous glucose monitoring; exenatide once weekly; glycaemic variability; type 2 diabetes

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article